Q32 Bio Inc. (NASDAQ: QTTB) is a Healthcare company (Biotechnology) with a market capitalization of $258M. The Maz Rating grades it against the other companies in its sector.
Q32 Bio Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $8.63, Q32 Bio Inc. trades at 2.7x trailing earnings, 4.8x sales and 1.0x book value. Over the last twelve months it generated about $54M of revenue and $94M of net income. It runs a gross margin of 99.8%, an operating margin of 34.2% and a net margin of 60.0%. It shows return on equity of 26.8%, return on invested capital of 6.3% and a free cash flow yield of -7.8%. On the balance sheet: a debt-to-equity ratio of 0.02 and a current ratio of 56.34. Over the past 52 weeks the share price ranged from $1.91 to $23.57, with a beta of -0.33.
Q32 Bio Inc. does not currently pay a dividend.
8 Wall Street analyst ratings cover the stock: 4 Buy and 4 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Q32 Bio Inc. (QTTB) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 160.8% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 160.8% / 33% · Receivables / Mkt Cap (36m) 0.31% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 160.8% / 33.33% · Receivables / Mkt Cap (24m) 0.31% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 3.58% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 91.9% / 33.33% · Receivables / Avg Assets (4Q) 1.45% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 97.4% / 33.33% · (Cash+Recv) / Total Assets 97.6% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
No. As of September 2026, Q32 Bio Inc. (QTTB) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Q32 Bio Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m).
Q32 Bio Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.